

August 21, 2024

Notice Regarding Offer of Refunds to 340B Covered Entities

Kedrion Biopharma Inc. (“Kedrion”) has identified a minor discrepancy in its calculation of the AMP for several products:

NDC9	Product Description
00562-7805	RhoGAM
76125-0667	Koate
76125-0790	Albuked
00562-7806	MICRhoGAM
76125-0150	KEDRAB

This resulted in a small variance in the 340B price for the product during 2023Q3, 2023Q4, 2024Q1, and 2024Q2. As a result of this minor discrepancy, Kedrion has determined that a small refund (for most, less than one dollar) may be owed to 340B Covered Entities that purchased these products during the relevant time period.

Kedrion has contacted covered entities who may be owed more than \$10 due to these adjustments. This notice is intended to give affected Covered Entities an opportunity to request refunds. Accordingly, if a Covered Entity believes that it has overpaid by less than \$10 in the aggregate for the impacted products during the restatement period, and the Covered Entity would like to request a refund, such Covered Entity should contact Kedrion directly via email at 340BProgram@kedrion.com. The Covered Entity may be asked to provide additional information for verification purposes, such as the applicable NDC(s), purchase volume(s) and time period(s). Upon validation that a requested refund is owed, Kedrion will approve the refund request. Kedrion will accept requests received on or before October 31, 2024.